Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB086550 in Japanese patients with advanced solid tumors
NCT04674748Phase 1Terminated
- Sponsor
- Incyte
- Start
- Feb 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of incb086550 in solid tumor, sponsored by Incyte. Primary endpoint: Treatment Emergent Adverse Events at 27 months. Started Feb 2021; status: terminated.
02
Drugs
incb086550
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04674748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04674748.